Dunner D, Kumar R
University of Washington Medical Center, Department of Psychiatry, Seattle 98105, USA.
Pharmacopsychiatry. 1998 May;31(3):89-101. doi: 10.1055/s-2007-979307.
The selective serotonin reuptake inhibitor paroxetine has been extensively studied and is now an established therapy for the treatment of depressive disorders. Paroxetine has demonstrated efficacy in major depression in both young and elderly patients, with an improved tolerability profile over conventional antidepressants. Paroxetine is effective across a continuum of anxiety and depressive disorders, including severe depression, depression with anxiety, comorbid depression and obsessive-compulsive disorder. The first agent of its class licensed for use in panic disorder, paroxetine has been shown to be effective in reducing the number of panic attacks and preventing relapse. A worldwide clinical database has established that paroxetine has a benign adverse event profile. Paroxetine therefore offers an effective and well tolerated treatment for a broad spectrum of psychiatric disorders.
选择性5-羟色胺再摄取抑制剂帕罗西汀已得到广泛研究,目前是治疗抑郁症的一种成熟疗法。帕罗西汀在年轻和老年患者的重度抑郁症治疗中均显示出疗效,与传统抗抑郁药相比,耐受性更佳。帕罗西汀对一系列焦虑症和抑郁症均有效,包括重度抑郁症、伴焦虑的抑郁症、共病性抑郁症和强迫症。作为该类药物中首个获批用于恐慌症的药物,帕罗西汀已被证明可有效减少恐慌发作次数并预防复发。一个全球临床数据库证实,帕罗西汀的不良事件特征良好。因此,帕罗西汀为广泛的精神疾病提供了一种有效且耐受性良好的治疗方法。